HQ
Cleveland, Ohio
Founded
2011
Founders and CEO
Al Hawkins, Co-Founder and CEO
Brian Kasper, Co-Founder
Sector
Life Sciences

Company Profile

Milo Biotechnology is a Cleveland, OH based company developing therapies to increase muscle strength and prevent muscle atrophy. The company’s lead program is a skeletal muscle specific transgene of the protein follistatin. The follistatin 344 transgene is delivered via an adeno-associated virus to achieve long lasting and potent expression in muscle. Milo is currently engaged in three clinical studies for rare muscular dystrophies. Milo Biotechnology’s therapy is based on adeno-associated virus (AAV) delivery of follistatin. AAVs are small, non-pathogenic carriers that can be tailored to deliver sustained administration of follistatin via a single dose.

Blogs About Milo Biotechnology

Milo Biotechnology Continues To Make News
JumpStart Inc. and Rev1 Ventures Announce Investment in Milo Biotechnology
Milo Biotechnology Develops Gene Therapy to Treat Muscular Dystrophy
Milo Biotechnology
Rev1 Ventures Announces Landmark Investment in Nationwide Children’s Hospital Spinout

Milo Biotechnology in the News

Nationwide Children’s spinoff raises funds for muscular dystrophy gene therapy trials from Rev1, JumpStart
Columbus Business First
Milo Biotechnology Announces FDA Orphan Drug Designation for Treatment of Inclusion Body Myositis
Milo Biotechnology Raises Funding from JumpStart and Rev1 Ventures
JumpStart Inc. and Rev1 Ventures Announce Investment in Milo Biotechnology
JumpStart Inc. and Rev1 Ventures Announce Investment in Milo Biotechnology